It’s hard to keep up with the rapidly unfolding paradigm shifts in the management of oligometastatic non-small cell lung cancer (NSCLC), a disease site that has arguably seen the most promising high-level data supporting remarkable survival advantages with definitive local treatment to all sites of disease. Questions abound regarding sequencing of therapies? Which local therapies? Does it matter if the oligomets are synchronous, metachronous, oligopersistent, or oligoprogressive? The list goes on and on. Luckily, ASTRO and ESTRO have teamed up to provide updated guidelines on clinical management that addresses all of the above. Table 6 in particular touches on radiation specifics, generally stating you pull no punches in regards to sophistication of technique in order to provide safe definitive ablative radiation doses to all sites of active disease. | Iyengar, Pract Radiat Oncol 2023
